# Fresenius Kabi

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed August 17, 2026.

> TYENNE (tocilizumab-aazg) is an FDA-approved biosimilar to Actemra® (tocilizumab) for the treatment of various inflammatory and autoimmune conditions, including moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis, CAR T cell-induced severe or life-threatening cytokine release syndrome, and hospitalized adult patients with COVID-19. It offers three administration options, including a pre-filled autoinjector pen.

- Business Profile: https://optimly.ai/brand/fresenius-kabi
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://biosimilars.fresenius-kabi.com/
- Logo: https://logo.clearbit.com/biosimilars.fresenius-kabi.com
- Slug: fresenius-kabi
- Brand Authority Index tier: Emerging
- Category: Prescription Pharmaceutical Medicines
- Last Analyzed: August 17, 2026